Less than 1 min.Read

Antisense Therapeutics: Raises $7.3M for DMD treatment

November 12, 2020

Antisense Therapeutics (ANP) has raised $7.3 million for its Duchenne muscular dystrophy (DMD) treatment
The company will issue 73 million shares at 10 cents each to new and existing shareholders
Additionally, it aims to raise a further $1 million under a share purchase plan (SPP)
The funds will be used to advance its applications of DMD treatment, known as ATL1102, in Europe and the U.S.
Additionally, earlier this week, Antisense commenced its journey to dual list on the Frankfurt Stock Exchange
On the market this afternoon, Antisense is down 8.70 percent and is trading for 10.5 cents per share